Spectrum and surgical outcomes of gastrointestinal stromal tumours

Abstract

Background: Surgery and imatinib are the mainstays of the management of gastrointestinal stromal tumours (GIST). This study aimed to analyse the outcomes in the management of GIST utilising surgery and imatinib.
Methods: Progression-free survival (PFS) and overall survival (OS) were analysed in relation to imatinib therapy, location of tumour, resection margins, type and extent of surgery. Imatinib was administered in the neoadjuvant (maximum 12 months) and adjuvant setting (minimum 36 months) and until disease progression or drug intolerance. Disease response was assessed with the Choi criteria. Survival analysis included calculation of PFS, OS and Kaplan–Meier curves.
Results: Sixty-two patients were reviewed and 56 had surgical resection. The median age (range) was 58.5 (8–95) years. The median PFS and OS (IQR) was 24.0 (0–52.0) and 41.0 (15.0–74.0) months, respectively. Thirty-nine (70%) patients were treated with imatinib, with 21 of these in a neoadjuvant setting. In the patients undergoing surgery, surgical margins were R0, R1 and R2 in 41 (75%), eight (15%) and six (11%) respectively. There was an insignificant difference in the
overall survival in these three groups. For those having liver metastasectomy and multivisceral resection, the PFS and OS were 32.5 (17.5–60.3) and 28.5 (5.75–49.8) (p = 0.008), and 96.0 (58.5–116) and 80 (50.5–92.3) months (p = 0.033), respectively.
Conclusion: Whilst the numbers were small, certain trends were observed. Surgery in combination with imatinib offers survival benefit in patients undergoing R0, R1, R2, liver metastases and multivisceral resections.